Journal Browser

Journal Browser

Special Issue "COVID and the Economics of Public Health"

A special issue of International Journal of Environmental Research and Public Health (ISSN 1660-4601). This special issue belongs to the section "Health Economics".

Deadline for manuscript submissions: 31 March 2022.

Special Issue Editors

Prof. Dr. Patrick Jeurissen
E-Mail Website
Guest Editor
IQ Healthcare Scientific Institute for Quality of Healthcare, Radboud Institute for Health Sciences, Radboud University Medical Center, 6525 GA Nijmegen, The Netherlands
Ministry of Health, Welfare and Sport, 2511 VX The Hague, The Netherlands
Interests: fiscal issues in health care; health systems; public health
Prof. Dr. Johan Polder
E-Mail Website
Guest Editor
Dutch Institute of Public Health and Environment, Tilburg University, 5037 AB Tilburg, The Netherlands
Interests: economics of public health

Special Issue Information

Dear Colleagues,

COVID-19 teaches us many lessons. One is about the importance of public health. Every day we can see how huge the negative consequences of a pandemic are, not only for global health, but also for the broader societies that face shrinking economies and increasing income disparities. Experts warned us for quite some time before COVID-19 arrived about these pandemic risks. COVID-19 raises important questions for the larger community of public health economists. How do we strengthen and increase the legitimacy of their analytical toolboxes?

This Special Issue seeks original contributions that analyze how the toolbox of public health economics can strengthen effective policies for pandemic outbreaks, such as COVID-19.

Submitted articles can cover a range of issues. What do we know about the cost-effectiveness of public health interventions that target COVID-19 and other infectious diseases? How can cost-effectiveness studies rigorously assess pandemic preparedness (including one-health initiatives)? What are the effects of the effective prevention of infectious diseases on the total costs of healthcare? How can more participative and interactive approaches in the field of HTA contribute to effective policymaking? What do we know about effective models of the governance for a cost-effectiveness analysis of public health? Just to name a few scholarly dilemmas.

We welcome a range of manuscripts: (systematic) reviews, empirical studies (quantitative, qualitative and mixed methods), perspectives, viewpoints, etc.

Prof. Dr. Patrick Jeurissen
Prof. Dr. Johan Polder
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Environmental Research and Public Health is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2300 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • public health
  • COVID-19
  • cost-effectiveness analysis (HTA)
  • political economy of public health
  • infectious diseases
  • governance
  • interactive HTA

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:


Impact of Mass Workplace COVID-19 Rapid Testing on Health and Healthcare Resource Savings
Int. J. Environ. Res. Public Health 2021, 18(13), 7129; https://0-doi-org.brum.beds.ac.uk/10.3390/ijerph18137129 - 03 Jul 2021
Cited by 2 | Viewed by 991
Background: The epidemiological situation generated by COVID-19 has cast into sharp relief the delicate balance between public health priorities and the economy, with businesses obliged to toe the line between employee health and continued production. In an effort to detect as many [...] Read more.
Background: The epidemiological situation generated by COVID-19 has cast into sharp relief the delicate balance between public health priorities and the economy, with businesses obliged to toe the line between employee health and continued production. In an effort to detect as many cases as possible, isolate contacts, cut transmission chains, and limit the spread of the virus in the workplace, mass testing strategies have been implemented in both public health and industrial contexts to minimize the risk of disruption in activity. Objective: To evaluate the economic impact of the mass workplace testing strategy as carried out by a large automotive company in Catalonia in terms of health and healthcare resource savings. Methodology: Analysis of health costs and impacts based on the estimation of the mortality and morbidity avoided because of screening, and the resulting savings in healthcare costs. Results: The economic impact of the mass workplace testing strategies (using both PCR and RAT tests) was approximately €10.44 per test performed or €5575.49 per positive detected; 38% of this figure corresponds to savings derived from better use of health resources (hospital beds, ICU beds, and follow-up of infected cases), while the remaining 62% corresponds to improved health rates due to the avoided morbidity and mortality. In scenarios with higher positivity rates and a greater impact of the infection on health and the use of health resources, these results could be up to ten times higher (€130.24 per test performed or €69,565.59 per positive detected). Conclusion: In the context of COVID-19, preventive actions carried out by the private sector to safeguard industrial production also have concomitant public benefits in the form of savings in healthcare costs. Thus, governmental bodies need to recognize the value of implementing such strategies in private settings and facilitate them through, for example, subsidies. Full article
(This article belongs to the Special Issue COVID and the Economics of Public Health)
Back to TopTop